Global Leading Market Research Publisher QYResearch announces the release of its latest report “Quercetin API – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Quercetin API market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Quercetin API was estimated to be worth US285millionin2025andisprojectedtoreachUS285millionin2025andisprojectedtoreachUS460 million by 2032, growing at a CAGR of 7.1% from 2026 to 2032. For nutraceutical formulators, pharmaceutical R&D scientists, and dietary supplement brand managers, the core business imperative lies in utilizing Quercetin API (active pharmaceutical ingredient) that addresses the critical need for a natural, broad-spectrum flavonoid (plant-derived polyphenol) with well-documented antioxidant (scavenges free radicals, upregulates Nrf2 pathway), anti-inflammatory (inhibits NF-κB, COX-2, LOX, reduces pro-inflammatory cytokines (IL-6, TNF-α)), anti-allergic (mast cell stabilizer, inhibits histamine release), antiviral (zinc ionophore (facilitates cellular zinc uptake) mechanism studied for SARS-CoV-2), immunomodulator, and senolytic (induces apoptosis of senescent cells) effects. Quercetin is naturally abundant in onions (highest concentration), apples, tea, red wine, berries (blueberries, cranberries), capers, broccoli, kale, and buckwheat. The API is manufactured via extraction from plant sources (primarily Sophora japonica (Japanese pagoda tree) buds or tartary buckwheat) followed by purification and hydrolysis, or via semi-synthesis from rutin (a glycosylated quercetin found in buckwheat). Key applications: anti-inflammatory (supplements for joint health, arthritis, rheumatism, gout, chronic inflammatory conditions), anti-allergy (allergic rhinitis (hay fever), asthma, food allergies, atopic dermatitis, mast cell activation syndrome (MCAS)), and others (cardiovascular health (lowers blood pressure, improves endothelial function), metabolic health (improves insulin sensitivity, reduces blood glucose), immune support (reduces severity, duration of viral illnesses, immune modulation), sports nutrition (reduces exercise-induced oxidative stress, inflammation), brain health (neuroprotection, reduces Alzheimer’s amyloid-beta aggregation), senolytic therapy (targets aging cells, promotes healthspan), and zinc ionophore (enhances cellular zinc uptake, studied in COVID-19 protocols). Purity grades: 98% (standard commercial grade for most nutraceutical and food applications) and 99% (high purity, for pharmaceutical research, premium supplements). Key suppliers: Carbone Scientific Co., Ltd (UK), Manus Aktteva Biopharma LLP (India), Fengchen Group Co., Ltd (China), Enomark (Canada), Inopha International Co., Limited (Hong Kong), Shanghai Bio-Tech Co., Ltd (China), Wuhan Kemike Biomedical Technology Co., Ltd (China). The market benefits from established supply chains (Sophora japonica cultivation in China) and growing consumer awareness of natural anti-inflammatory and immune-support compounds.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/releases/5975748/quercetin-api
The Quercetin API market is segmented as below:
Carbone Scientific Co., Ltd
Manus Aktteva Biopharma LLP
Fengchen Group Co.,Ltd
Enomark
Inopha International Co., Limited
Shanghai Bio-Tech Co., Ltd
Wuhan Kemike Biomedical Technology Co., Ltd
Segment by Type
0.98
0.99
Others
Segment by Application
Anti-inflammatory
Anti-allergy
Others
1. Market Drivers: Immune Health Demand, Senolytics Research, and Established Supply Chain
Several powerful forces are driving the Quercetin API market:
Post-COVID immune health and zinc ionophore awareness – Quercetin as zinc ionophore (transport zinc into cells, inhibiting viral replication) gained widespread attention (Zelenko protocol). Supplements sales surged 300%+ 2020-2021, then stabilized. Ongoing COVID-19 and flu seasons drive demand.
Senolytics and longevity research – Quercetin + Dasatinib (D+Q) combination is one of the first senolytic therapies (clears senescent cells, improves healthspan). Human clinical trials (Alzheimer’s, osteoarthritis, frailty, kidney disease). Growing longevity supplement market (NMN, resveratrol, fisetin, spermidine, quercetin).
Established, low-cost supply chain – Sophora japonica (Japanese pagoda tree) cultivated in China (Shanxi, Henan, Shaanxi) for rutin extraction. Quercetin API cost US30−80/kg(9830−80/kg(9850-150/kg (99%). Volume enables mass-market nutraceutical pricing.
Recent market data (December 2025): According to Global Info Research analysis, 98% purity quercetin API dominates with approximately 70% revenue share (standard nutraceutical grade). 99% purity holds 25% share (high-purity, research, premium supplements). Other grades 5% share. Anti-inflammatory applications (joint health, arthritis, chronic inflammation) largest segment (60% share). Anti-allergy applications (seasonal allergies, mast cell disorders) 30% share. Others (cardiovascular, senolytic, sports) 10% share. Asia-Pacific (China, India) dominates API manufacturing (80%+ share) (Sophora japonica source). North America (supplement formulation) 30% demand share. Europe 25% share. China exporters (Fengchen Group, Shanghai Bio-Tech, Wuhan Kemike) dominate global supply.
2. Product Specifications and Applications
| Purity Grade | Standardization | Major Source | Typical Price (USD/kg) | Primary Applications | Share |
|---|---|---|---|---|---|
| 98% | UV (Ultraviolet-Visible) / HPLC | Sophora japonica, buckwheat | US$30-80 | Dietary supplements, functional foods, nutraceuticals | ~70% |
| 99% | HPLC (High-Performance Liquid Chromatography) | Sophora japonica (high purity refined) | US$50-150 | Pharmaceutical research, premium supplements, clinical trials | ~25% |
Key specifications: CAS number (117-39-5). Molecular formula (C15H10O7). Molecular weight (302.24 g/mol). Appearance (yellow powder). Assay (≥95-99% anhydrous basis). Heavy metals (Pb <1 ppm, As <1 ppm). Residual solvents (ethanol <5000 ppm). Loss on drying (<5%). Total plate count (<1000 CFU/g). Bulk density (0.4-0.7 g/mL). Solubility (practically insoluble in water, soluble in ethanol, DMSO, alkali solutions). Bioavailability: low (≈2-5%). Enhancers (piperine, phytosome formulation, liposomal encapsulation) often co-formulated. Stability (2-3 years in dry, dark, cool conditions). Standardization markers by HPLC (quercetin aglycone content).
Exclusive observation (Global Info Research analysis): Quercetin API market is dominated by Chinese manufacturers (Fengchen Group, Shanghai Bio-Tech, Wuhan Kemike, Inopha International) leveraging Sophora japonica cultivation (Shanxi, Henan). India (Manus Aktteva Biopharma) also produces, at slightly higher cost. Unlike biotech-derived antioxidants (ergothioneine), quercetin is a low-cost commodity starting material. 98% grade for supplements, 99% for research and premium brands (Life Extension, NOW Foods, Thorne, Pure Encapsulations, Quercetin Phytosome by Indena). Bioavailability enhancement (Lypo-Spheric quercetin, phytosome) commands premium priced finished products. Senolytic formulations (quercetin + dasatinib) are investigational not yet commercial supplements (medical food status).
User case – seasonal allergy supplement (December 2025): NOW Foods sells Quercetin with Bromelain (500mg quercetin + 100mg bromelain) for seasonal allergy relief (hay fever). Retail US$21.99 per 120 capsules. API sourced from Fengchen Group (98% purity).
User case – senolytic clinical trial (January 2026): US clinical trial for Alzheimer’s disease uses Quercetin (500mg) + Dasatinib (100mg), intermittent dosing (3 consecutive days/week). Pharmaceutical-grade 99% purity API sourced from Carbone Scientific or Manus Aktteva.
3. Key Challenges and Technical Difficulties
Very low oral bioavailability (≈2-5%) – Quercetin aglycone poorly absorbed (glucuronidated, methylated in gut). Rapid elimination. Solutions: phytosome (lecithin-bound), liposomal encapsulation, co-administration with piperine (black pepper extract), or enzymatically modified isoquercitrin (EMIQ, more bioavailable). Most supplements still use plain quercetin.
Poor water solubility (practically insoluble) – Limits formulation in beverages, liquid supplements, and aqueous skin care. Cyclodextrin complexation, nanoparticle, or solubilized formulations required.
Technical difficulty – microbiological contamination from plant source: Sophora japonica buds may contain high gram-negative bacteria (endotoxin), mold, yeast. Gamma irradiation or ethylene oxide sterilization used. Heavy metals can be elevated.
Technical development (October 2025): Fengchen Group (China) introduced micronized quercetin API (particle size D90 <20µm). Enhanced solubility and dissolution rate. Optimized for capsule and tablet formulation. Price premium 20-30% over standard 98%.
4. Competitive Landscape
Key players include: Carbone Scientific Co., Ltd (UK – research-grade), Manus Aktteva Biopharma LLP (India – manufacturer), Fengchen Group Co., Ltd (China – largest exporter), Enomark (Canada – distribution), Inopha International Co., Limited (Hong Kong – trader), Shanghai Bio-Tech Co., Ltd (China – manufacturer), Wuhan Kemike Biomedical Technology Co., Ltd (China – manufacturer). Hebei Xinqidian Biotechnology, Xi’an Sost Biotech not listed. China suppliers dominate global volume (80%+).
Regional dynamics: China (Sophora japonica source, manufacturing) dominant; India (Manus Aktteva) smaller; US, Europe import. Supplement brands (NOW, Life Extension, Thorne, Pure Encapsulations, Jarrow) specify purity, solvent residues, microbial limits.
5. Outlook
Quercetin API market will grow at 7.1% CAGR to US$460 million by 2032, driven by immune health, anti-inflammatory supplements, and senolytic research. Technology trends: micronized quercetin, phytosome (bioavailable), liposomal formulations, and combination with zinc, bromelain, vitamin C. China will continue to dominate API supply. Senolytic clinical trial outcomes (Alzheimer’s, aging) could drive new market expansion beyond 2030.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
